D-Glucosamine Sulfate Potassium Chloride Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is the compendial mixed salt composed of two glucosamine cations, one sulfate anion, and two potassium chloride units per formula unit. It is supplied as a white to almost white crystalline powder and is intended solely for further processing into finished pharmaceutical products; it is not a sterile, ready-to-administer drug. The product model is the pharmacopoeial salt identity rather than a discrete instrument designation. On an anhydrous, solvent-free basis, one gram of nominal material contains approximately 592 mg glucosamine base, 129 mg potassium, 117 mg chloride, and 159 mg sulfate. This fixed stoichiometry drives the handling, labelling, and compatibility boundaries that distinguish the material from glucosamine hydrochloride and from sodium chloride-stabilised glucosamine sulfate.

What Distinguishes the Potassium Chloride-Stabilised Sulfate Salt from Sodium Chloride and Hydrochloride Forms?

Direct weight-for-weight substitution among glucosamine salts is not valid. Glucosamine hydrochloride contains approximately 831 mg of glucosamine base per gram; the sodium chloride-stabilised sulfate contains approximately 625 mg base per gram; the present potassium chloride-stabilised sulfate contains approximately 592 mg base per gram. A target of 1500 mg glucosamine base therefore requires approximately 1806 mg of glucosamine hydrochloride, 2400 mg of glucosamine sulfate sodium chloride, and 2535 mg of glucosamine sulfate potassium chloride. These differences alter tablet size, capsule fill mass, sachet weight, and dissolution calibration. The potassium salt contributes approximately 327 mg potassium (8.4 mEq) per equivalent base dose, whereas the sodium salt contributes approximately 192 mg sodium (8.3 mEq). This cation load must be declared on the finished-product label and assessed in sodium-restricted or potassium-restricted populations. Published clinical trial data for the potassium chloride-stabilised salt are less extensive than for the sodium chloride-stabilised form; equivalence cannot be assumed from stoichiometry alone.

In oral solid-dose processing, crystal habit and moisture interaction dominate the manufacturing control strategy. Direct compression of as-received powder is frequently impractical because of low bulk density, poor gravity flow, and electrostatic adhesion to punch faces. Roller compaction is therefore used before tablet compression for many formulations. The compaction endpoint is established by incremental roll-pressure studies and confirmed by sieve analysis, bulk density, and tapped density according to USP <616> or Ph. Eur. 2.9.34. At relative humidity above 50%, the powder softens and deposits on compression tooling; the press room is supplied with dehumidified air having a dew point below 8°C. Magnesium stearate is omitted above 0.8% w/w because hydrophobic lubricant overblending can delay release of the highly water-soluble API. When used, lubricant blending is limited to 5 minutes in a bin blender at 12 rpm, with compression force and ejection force recorded continuously. Dissolution is evaluated according to USP <711> or Ph. Eur. 2.9.3; method selection depends on the finished dosage form and the salt’s pH-dependent solubility.

Wet granulation of the sulfate potassium salt with water as the sole granulation fluid can generate hard agglomerates through local dissolution and recrystallisation during drying. Aqueous granulation is therefore replaced by roller compaction or by hydroalcoholic granulation at low water activity. When fluid-bed drying is used, product temperature is kept below 45°C to limit discolouration from the reducing sugar moiety, and the inlet air dew point is controlled at or below 4°C for moisture-sensitive batches. Residual solvent from hydroalcoholic processing is measured by USP <467> or Ph. Eur. 2.4.24. Granules intended for sachet filling are milled to a target D50 between 180 and 250 μm and dried to a loss-on-drying value not exceeding the compendial limit before filling.

Specification Benchmarks and Analytical Release Matrix

The non-sterile oral powder is controlled for appearance, identity, assay, loss on drying, residue on ignition, specific optical rotation, chloride, sulfate, potassium, related compounds, residual solvents, elemental impurities, and microbial quality. Compendial identity tests include infrared absorption spectrophotometry, potassium and sulfate precipitation reactions, and optical rotation measured by Ph. Eur. 2.2.7. Because the molecule lacks a strong UV chromophore, assay is performed by ion-pair HPLC with charged aerosol detection or refractive index detection; UV detection at low wavelength alone is not sufficiently selective. The assay is expressed on the dried basis, and the compendial acceptance range is typically 98.0 to 102.0%. Potassium-to-chloride molar ratio is used as an orthogonal confirmation of salt stoichiometry; a ratio deviating from 1.0 suggests a mislabelled mixture or analytical interference.

For oral non-sterile presentations, microbial enumeration testing by USP <61> and USP <62> is applied with acceptance criteria such as total aerobic microbial count not more than 10³ CFU/g, total combined yeasts and molds not more than 10² CFU/g, and absence of Escherichia coli and Salmonella. Elemental impurities are managed by ICH Q3D; batch testing by inductively coupled plasma mass spectrometry according to USP <233> is used when risk assessment indicates routine verification. Residual solvents are controlled by Ph. Eur. 2.4.24 or USP <467>; no Class 1 solvent should be used in the supplied API. Endotoxin and sterility are not implied by the non-sterile oral grade; the label must distinguish oral non-sterile grade from injectable grade.

When Terminal Sterilization of Injectable Glucosamine Sulfate Potassium Chloride Is Considered

The injectable grade is not automatically sterile; it is a low-endotoxin, low-bioburden active ingredient intended for downstream sterile filtration or terminal sterilization in the finished-product line. Aqueous solutions are acidic and are usually filtered through a 0.22 μm sterilising-grade membrane under aseptic conditions. Terminal autoclaving at 121°C for 15 minutes can produce discolouration and degradation products because the glucosamine molecule contains a reducing sugar centre that is susceptible to heat-induced reactions, especially in the presence of reducing carbohydrates or primary amines. Compatibility of the sulfate potassium salt with a given sterilization cycle must therefore be confirmed by forced-degradation studies and finished-product stability data; no universal autoclave condition is assigned by the monograph.

For injectable presentation, bacterial endotoxin limits are not fixed solely by the API monograph; they are calculated from the maximum intended bolus dose using the K/M formula in USP <85>. The manufacturer must also control visible particulate matter, sub-visible particulate matter by USP <788> or Ph. Eur. 2.9.19, and container–closure integrity. The potassium content in an injectable formulation must be incorporated into the electrolyte balance of the finished infusion; use with potassium-containing diluents can shift the final potassium concentration beyond the label claim. Published data for this specific configuration are limited, so formulation-scale compatibility and stability runs are required before registration batches.

Granule presentations use the same dry-milled salt in sachets or stick-packs. The principal formulation constraint is electrostatic charging and bulk-density variation during filling. Static charge can adhere powder to vertical form-fill-seal contact surfaces and create fill-weight drift across a production run. The filling system is therefore grounded, and relative humidity during sachet filling is maintained between 35% and 45% RH to reduce charge accumulation while avoiding moisture pickup. Fill weight is corrected for water content; the target glucosamine base dose is divided by the certified base content per gram. A lot with 592 mg/g base content requires 2.53 g of actual lot mass for a 1500 mg base dose if loss on drying is negligible. If lot moisture content is 1.0%, the required mass is approximately 2.56 g. The same correction applies to tableting and encapsulation calculations.

Comparative Salt-Form Stoichiometry and Process Consequences

The following table summarises calculated compositional differences on an anhydrous basis. These values are stoichiometric, not clinical efficacy determinations.

The choice of salt form in product development is a manufacturing and patient-safety decision, not a routine substitution. The sulfate salts supply sulfate anion, which is absent in glucosamine hydrochloride; the hydrochloride salt carries no potassium or sodium, but its high chloride content may affect the electrolyte composition of oral solutions. The sodium salt is unsuitable for sodium-restricted labels, and the potassium salt introduces a potassium load that must be quantified. In parenteral formulations, the potassium content of this product restricts its use in admixtures already containing potassium chloride; in oral formulations, the same potassium content is used to calculate daily electrolyte load. The finished-product label must specify the exact salt name, and the drug master file should record the stoichiometric basis used for the active-content claim.

Residual solvents and elemental impurities are not batch-release afterthoughts. For fermentation-derived lots, the supplier’s process must demonstrate reduction of fermentation residues; for chitin-derived lots, the finished-dose manufacturer must assess residual protein and allergen risk because the compendial monograph may not include a shellfish-protein test. The API should be stored in tightly closed containers at controlled room temperature and protected from moisture; if the container is opened at relative humidity above 60%, pre-drying before processing is recommended. The material is incompatible with strong oxidising agents and with amine-bearing excipients under high-moisture thermal stress because the reducing sugar can enter Maillard-type browning reactions. No oxidation or acid hydrolysis should be performed without a stability evaluation. Published data for this specific configuration are limited; process qualification must therefore be run on the actual lot, on the actual equipment, and with the final contact materials.